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ated with slower decline. While LTOCs used control groups, 
adjusted for multiple covariates, had higher external validity, 
and favorable ethical, practical and cost considerations, their 
limitations included potential selection bias due to lack of 
placebo comparisons and randomization.  Conclusions: Nat-
uralistic LTOCs provide complementary long-term level II 
evidence to complement level I evidence from short-term 
RCTs regarding therapeutic effectiveness in AD that may 
otherwise be unobtainable. A coordinated strategy/consor-
tium to pool LTOC data from multiple centers to estimate 
long-term comparative effectiveness, risks/benefits, and 
costs of AD treatments is needed. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Alzheimer’s disease (AD) is a chronic and progressive 
disease with a course of illness that spans many years, and 
in some individuals can stretch to more than a decade. 
Randomized controlled trials (RCTs) serve as the scien-
tific gold standard for therapeutic efficacy and are re-
quired for regulatory approval of AD interventions, but 
are not without limitations. RCTs are often short-term 
studies performed in leveraged populations that cannot 
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 Abstract 
 Background: Randomized controlled efficacy trials (RCTs), 
the scientific gold standard, are required for regulatory ap-
proval of Alzheimer’s disease (AD) interventions, yet provide 
limited information regarding real-world therapeutic effec-
tiveness.  Objective: To compare the nature of evidence re-
garding the combination of approved AD treatments from 
RCTs versus long-term observational controlled studies 
(LTOCs).  Methods: Comparisons of strengths, limitations, 
and evidence level for monotherapy [cholinesterase inhibi-
tor (ChEI) or memantine] and combination therapy (ChEI + 
memantine) in RCTs versus LTOCs.  Results: RCTs examined 
highly selected populations over months. LTOCs collected 
data across multiple AD stages in large populations over 
many years. RCTs and LTOCs show similar patterns favoring 
combination over monotherapy over placebo/no treatment. 
Long-term combination therapy compared to monotherapy 
reduced cognitive and functional decline and delayed time 
to nursing home admission. Persistent treatment was associ-
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adequately inform about the long-term safety, risk-bene-
fit calculus, and comparative costs of real-world clinical 
treatments  [1, 2] . 
 Long-term naturalistic observational cohort (LTOC) 
studies supply level II grade evidence and can provide 
critical information regarding effects of treating typical 
patients under conditions of usual clinical care; however, 
they are undervalued in AD for not providing random-
ized level I (RCT) grade evidence  [3, 4] . This dilemma in 
clinical medicine and health policy is neither new nor 
unique to AD, nor was it novel in 1967 when Schwartz 
and Lellouch  [5] elegantly analyzed these approaches and 
stated that ‘most therapeutic trials are inadequately for-
mulated, and this from their earliest stages of conception 
… in that the trials may be aimed at the solution of one 
or other of two radically different kinds of problem’. They 
made a distinction between two different and comple-
mentary conditions and approaches, the explanatory ver-
sus pragmatic trial. The former is performed under 
‘equalized’ and ‘optimized’ laboratory conditions, while 
the latter is performed under ‘normal’ and ‘practical’ 
conditions. This brief paper presents an overview of the 
nature of evidence with respect to comparative strengths, 
limitations and evidence levels for RCTs versus LTOCs 
for the only FDA-approved treatments of AD, cholines-
terase inhibitors (ChEIs) and memantine. 
 Methods 
 We compared the evidentiary level for ChEI and/or meman-
tine treatment studies including systematic database reviews/me-
ta-analyses, RCTs, open-label extensions of RCTs (RCTOLEX) 
and observational cohort studies. 
 Results 
 RCTs across the AD severity spectrum provide level I 
(highest grade) evidence for 24- to 28-week on-label (FDA 
indication) stage-appropriate treatment efficacy and 
safety of ChEIs and memantine as mono- or combination 
therapy in AD. While the majority of these RCTs evalu-
ated efficacy of ChEIs or memantine monotherapy  [6–
12] , several have assessed efficacy of combination therapy 
(ChEI + memantine)  [13, 14] . Limitations of these RCTs 
include their performance under idealized conditions in 
highly selected samples with strict inclusion/exclusion, 
treatment adherence and monitoring criteria, and rela-
tively short durations (approx. 6 months, except for two 
52-week RCTs with donepezil  [15, 16] ) relative to the 
course of AD dementia (approx. 5–15+ years). Despite 
providing further support for cognitive and functional 
benefits of sustained treatment with a ChEI over several 
years, a controversial community-based long-term RCT 
(AD 2000)  [17] was hampered by design flaws (e.g. sev-
eral on-off titrations, site-level dropout, high likelihood 
of selection bias, underpowered) and excessive attrition 
( 1 97% at year 3) making interpretation problematic, and 
the study failed to provide level I grade evidence. In re-
sponse, the ongoing DOMINO-AD study  [18] , a long-
term RCT, was launched. An important gap in the data 
that is to be assessed by the DOMINO-AD study is the 
comparison of combination therapy versus memantine 
alone (as well as vs. ChEI alone and vs. placebo); results 
from this landmark UK study are highly anticipated. 
 RCTOLEX studies provide level II-3 (level IIb/c) sup-
port for the benefits of sustained treatment with ChEIs 
for up to several years  [19–22] and with memantine for 24 
weeks  [23] . RCTOLEX studies have additional limita-
tions that include potential confounds due to possible ef-
fects of differential attrition, unblinding, and the absence 
of a control group for comparison during the open-label 
phase  [24] . 
 Several systematic reviews/meta-analyses, including 
from the Cochrane database, provide level I evidence for 
the short-term, on-label, and stage-appropriate efficacy 
of ChEIs and/or memantine in AD; these include evi-
dence of the benefits of ChEIs  [25, 26] and memantine 
 [27] in cognition, the benefits of memantine in global se-
verity, cognition, function, and behavior  [28] , and quan-
tification of small to medium standardized effect size es-
timates, Cohen’s d of approximately 0.1–0.4, that favor 
ChEI treatment over placebo  [29, 30] , and memantine or 
ChEI + memantine combination over placebo  [28] in AD. 
 In comparison with data from the above studies, pro-
spectively collected data from several naturalistic LTOC 
studies of patients with AD treated in the clinical setting 
provide level II-1/2 (level IIa/b) evidence for the effective-
ness of ChEIs and combination therapy (ChEI + meman-
tine)  [31, 35] . Relative to RTC populations, LTOC studies 
include subjects with significant comorbidities, greater 
concomitant and neuropsychoactive medications, and 
imperfect treatment adherence. Naturalistic LTOC stud-
ies also include larger populations (sample size of approx. 
380–950), they have no strict inclusion/exclusion criteria 
(other than clinical criteria for AD), longer durations 
(mean follow-up of approx. 2.5–4 years), assessment of 
measures other than those required for regulatory ap-
proval, and gather data over multiple AD stages. Overall, 
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these studies provide evidence for sustained clinical ef-
fectiveness of ChEIs  [31, 34, 35] and combination therapy 
 [31] , with superiority of combination therapy over time in 
reducing decline in cognition ( fig.  1 a) and function 
( fig. 1 b)  [31] , delaying time to nursing home placement 
 [32] , and providing more benefit with greater persistence 
in treatment  [31, 33] . Cohen’s d effect size estimates for 
treatment benefits of combination therapy versus ChEI 
monotherapy range from 0.1 to 0.5 for cognition and 
from 0.2 to 0.7 for daily function and increase over 4 years 
 [31] . Limitations of these LTOC data include lack of ran-
domization, use of control cohorts without the same 
start/stop dates as treatment cohorts, and lack of meman-
tine monotherapy cohorts. 
 Discussion 
 ‘Most real problems contain both explanatory and 
pragmatic elements, for ethical reasons. Most trials hith-
erto have adopted the explanatory approach without 
question; the pragmatic approach would have often been 
more justifiable’  [5] . Naturalistic LTOC studies provide 
this type of useful pragmatic data to assess long-term 
treatment effects in AD. Naturalistic LTOC studies in AD 
provide level II grade evidence, have a high external, eco-
logical, content and convergent validity, and support data 
from short-term RCTs that ChEI and memantine combi-
nation is superior to ChEI alone in reducing long-term 
cognitive and functional decline, and delaying nursing 
home admission. Furthermore, LTOC studies support 
that benefits of ChEIs and memantine increase with per-
sistence in therapy and over time. While short-term ex-
planatory RCTs in AD remain a gold standard, they are a 
means to drug approval, not the end of assessment and 
discussion regarding treatment benefits and safety. Ethi-
cal considerations must take precedence over trial design, 
practical considerations will follow; as such, LTOC stud-
ies provide important information that may otherwise be 
impractical to obtain. 
 LTOC data complement data from RCTs and can it-
eratively inform their design and implementation. 
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 Fig. 1. Reduction of long-term cognitive 
and functional decline in AD patients on 
combination therapy with ChEI and me-
mantine – evidence from a naturalistic 
LTOC study [31].  a Trajectory of decline 
predicted over 4 years for groups of pa-
tients with AD starting with 10 errors on 
the Blessed Dementia-Information Mem-
ory Concentration scale (BDS; MMSE 
score of approx. 22) is lowest in the ChEI + 
memantine combination therapy group.
 b Trajectory of decline predicted over 4 
years for groups of patients with AD start-
ing with 25% dependence on the Wein-
traub Activities of Daily Living Scale 
(ADL) is lowest in the combination thera-
py group. 
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